Montelukast added to standard therapy in moderate exacerbations of asthma in children 6 to 14 years old

Abstract

This study is a double blind placebo controlled clinical trial conducted in pediatric patients 6-14 years of age admitted to the Pediatric Emergency Services Hospital Víctor Lazarte Echegaray EsSalud IV, diagnosed with moderate exacerbation of asthma, during the period March to August 2013.The working hypothesis was whether the administration of oral montelukast added to standard therapy in the treatment of moderate exacerbations of asthma is more effective than the administration of standard therapy alone in this patient group.142 children entered the study, which were randomly and assigned to two groups of 71 patients each. The treatment group received 5 mg of oral montelukast added to standard therapy service. The placebo group received a tablet of identical physical characteristics to montelukast 5mg. Assessed at baseline and 4 hours after, the MPIS (Modified Pulmonary Index Score) and % PEF (peak expiratory flow rate) in both groups. The results of this study demonstrate that there is no statistically significant difference in the decrease MPIS and increase % PEF in both study groups.